FDA approves Impax’s Emverm
HAYWARD, Calif. — Impaz Laboratories announced Friday that the Food and Drug Administration had approved its treatment for pinworm, whipworm, common roundworm, common hookworm and American hookworm. Emverm (mebendazole) is a chewable 100-mg tablet that the company said offers a 95% clinical cure rate for pinworm.
“We are pleased to announce the approval of EMVERM, a new prescription product for the treatment of pinworm and certain worm infections," Impax president and CEO Fred Wilkinson said. “As part of our life cycle plan to enhance our anthelmintic franchise in addition to Albenza (albendazole), with this approval, we can now offer an anthelmintic to treat the most common worm infections in the United States.”
The company said it hopes to make the drug available in the second quarter of 2016.